ILARIS canakinumab

Drug Class

Interleukin-1 beta (IL-1β) blocker

Mechanism

Canakinumab binds to human IL-1β with high affinity, neutralizing its activity and preventing its interaction with IL-1 receptors to resolve inflammation.

Approved Indication

Treatment of Periodic Fever Syndromes, including Cryopyrin-Associated Periodic Syndromes (CAPS); Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS); Still's Disease (AOSD and SJIA); and gout flares.

What This Means For Patients

ILARIS is not distributed through mainland China's retail pharmacy network. Uwell Cloud can help arrange a purchase channel for this medicine, sourced and dispatched from Hong Kong; clinical administration support in China can be coordinated on request. Availability and eligibility for any specific patient are determined by clinical review.

Regulatory Approvals

• FDA — Approved (2009) — Sources
• EMA — Approved (2009) — Sources

Pivotal Clinical Evidence

• CACZ885D2304 — Lachmann et al., N Engl J Med 2009 (NCT00465985) — Sources

Sources

• https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125287s063lbl.pdf
• https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris
• https://doi.org/10.1056/NEJMoa0810787